(Q38058958)

27 August 2017

Advances in treatment of bacterial meningitis (English)

1 reference

27 August 2017

1 reference

Guy E Thwaites

3

0 references

Diederik van de Beek

object named as

Diederik van de Beek

series ordinal

1

0 references

author name string

Matthijs C Brouwer

series ordinal

2

1 reference

PubMed ID

23141618

27 August 2017

Allan R Tunkel

series ordinal

4

1 reference

PubMed ID

23141618

27 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

380

1 reference

27 August 2017

9854

1 reference

27 August 2017

1693-1702

1 reference

Bacterial meningitis in the United States, 1998-2007.

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Clinical features and prognostic factors in adults with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Community-acquired bacterial meningitis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Practice guidelines for the management of bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

The diagnosis and management of acute bacterial meningitis in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Nosocomial bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Combined intrathecal and intramuscular gentamicin for gram-negative meningitis. Pharmacologic study of 21 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Resistance among Streptococcus pneumoniae: Implications for drug selection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Mortality in penicillin-resistant pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Neisseria meningitidis: evolution of penicillin resistance and phenotype in a children's hospital in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. The Active Bacterial Core Surveillance (ABCs) Team.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Clinical data in children with meningococcal meningitis in a Spanish hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

High-level chloramphenicol resistance in Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Community-acquired Listeria monocytogenes meningitis in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Acute bacterial meningitis in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Community-associated meticillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Strategies and new developments in the management of bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Outpatient gatifloxacin therapy and dysglycemia in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Linezolid for the treatment of patients with central nervous system infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Management of meningitis due to antibiotic-resistant Acinetobacter species

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Pathogenesis and pathophysiology of pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Corticosteroids for acute bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Lack of effectiveness of dexamethasone in neonatal bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Dexamethasone in adults with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Adjunctive dexamethasone in adults with meningococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Cognitive outcome in adults after bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Dexamethasone and long-term outcome in adults with bacterial meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Reducing intracranial pressure may increase survival among patients with bacterial meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Drug Insight: adjunctive therapies in adults with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Seizures in adults with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Hyperglycemia in bacterial meningitis: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961186-6

7 January 2021

10.1016/S0140-6736(12)61186-6

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23141618